Summary
The oxidative metabolism of bufuralol is under the same genetic control as that of debrisoquine and sparteine. 154 fasting volunteers received a 30 mg tablet of bufuralol and a blood sample was taken 3 h later. In poor metabolizers (8% of the sample) the plasma bufuralol concentrations were very high and the metabolite concentrations were low. The genetic oxidative status is a major source of interindividual variation in the plasma concentration of drugs that undergo oxidative metabolism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alvan G, von Bahr C, Seideman P, Sjöqvist F (1982) High plasma concentrations of β-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet 1: 333
Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU (1980) Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol 17: 153–155
Dayer P, Kubli A, Kupfer A, Courvoisier F, Balant L, Fabre J (1982a) Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol 13: 750–752
Dayer P, Balant L, Courvoisier F, Kupfer A, Kubli A, Gorgia A, Fabre J (1982b) The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet 7: 73–77
Dengler HJ, Eichelbaum M (1977) Polymorphismen und Defekte des Arzneimittelstoffwechsels als Ursache toxischer Reaktionen. Arzneim Forsch 27: 1836–1844
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187
Eichelbaum M (1982a) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokinet 7: 1–22
Eichelbaum M, Bertilsson L, Säwe J, Zekorn C (1982b) Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. Clin Pharmacol Ther 31: 184–186
Evans Price DA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105
Francis RJ, Allen JG, East PB, Ruane RJ (1976) The metabolism of bufuralol: Urinary metabolite profiles in rat, dog and man. Eur J Drug Metab Pharmacokinet 2: 113–124
Haefelfinger P (1980) Determination of bufuralol and its major metabolites in plasma by high-performance liquid chromatography. J Chromatogr 221: 327–335
Idle JR, Sloan TP, Smith RL, Wakile LA (1979a) Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man. Br J Pharmacol 66: 430P
Idle JR, Ritchie JC, Smith RL (1979b) Oxidation phenotype and metiamide metabolism. Br J Pharmacol 66: 432P
Idle JR, Islam SI (1981) Polymorphism of phenformin 4-hydroxylation in Saudi females. Br J Pharmacol 73: 177P-178P
Kates RE, Harrison DC, Winkle RA (1982) Metabolite cumulation during long-term oral encainide administration. Clin Pharmacol Ther 31: 427–432
Kitchen I, Tremblay J, André J, Dring LG, Idle JR, Smith RL, Williams RT (1979) Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 9: 397–404
Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586
Mellström B, Bertilsson L, Säwe J, Schulz HU, Sjöqvist F (1981) E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 30: 189–193
Minder EI, Müller HK, Meier PJ, Meyer UA (1982) Direct measurement of the activity of the cytochrome P450 isozyme related to polymorphic debrisoquine metabolism in human liver. Abstracts of the 8th European Workshop on Drug Metabolism, September 1982, Liège
Schulz P, Balant L, Dayer P, Kubli A, Guertsch C, Garrone G (1982) The disposition of amitriptyline in humans who are normal and poor hydroxylators. Abstracts of the 13th Congress of the Collegium Internationale Neuro-Psychopharmacologicum, June 1982, Jerusalem
Shah RR, Oates NS, Idle JR, Smith RL (1980) Genetic impairment of phenformin metabolism. Lancet 1: 1147
Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF (1982a) Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 284: 295–299
Shah RR, Oates NS, Idle JR, Smith RL (1982b) Beta-blockers and drug oxidation status. Lancet 1: 508–509
Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL (1978) Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J 2: 655–657
Sloan TP, Idle JR, Smith RL (1981) Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther 29: 493–497
Waring RH, Mitchell SC, Idle JR, Smith RL (1981) Genetically determined impaired drug sulphoxidation. Lancet 1: 778
Woosley RL, Roden DM, Duff HJ, Carey EL, Wood AJJ, Wilkinson GR (1981) Co-inheritance of deficient oxidative metabolism of encainide and debriosquine. Clin Res 29: 510A
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dayer, P., Balant, L., Küpfer, A. et al. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents. Eur J Clin Pharmacol 24, 797–799 (1983). https://doi.org/10.1007/BF00607090
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607090